287 related articles for article (PubMed ID: 33864688)
1. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
[TBL] [Abstract][Full Text] [Related]
2. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
Bigos R; Solomon E; Dorfman JD; Ha M
J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
[TBL] [Abstract][Full Text] [Related]
3. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Walker CK; Sandmann EA; Horyna TJ; Gales MA
Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
[TBL] [Abstract][Full Text] [Related]
4. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.
Costantini TW; Min E; Box K; Tran V; Winfield RD; Fortlage D; Doucet J; Bansal V; Coimbra R
J Trauma Acute Care Surg; 2013 Jan; 74(1):128-33; discussion 134-5. PubMed ID: 23271087
[TBL] [Abstract][Full Text] [Related]
5. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
6. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
7. Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients.
Thind T; Heye T; Henson C; Reif R; Jensen HK; Kalkwarf KJ; Bhavaraju A; Robertson R; Jenkins A
Am Surg; 2024 Jun; 90(6):1406-1411. PubMed ID: 38518208
[TBL] [Abstract][Full Text] [Related]
8. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
9. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
Bickford A; Majercik S; Bledsoe J; Smith K; Johnston R; Dickerson J; White T
Am J Surg; 2013 Dec; 206(6):847-51, discussion 851-2. PubMed ID: 24070664
[TBL] [Abstract][Full Text] [Related]
10. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
Hart K; Andrick B; Grassi S; Manikowski J; Graham J
Ann Pharmacother; 2021 Sep; 55(9):1120-1126. PubMed ID: 33455432
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients.
Yam L; Bahjri K; Geslani V; Cotton A; Hong L
Pharmacotherapy; 2019 Jul; 39(7):749-755. PubMed ID: 31112313
[TBL] [Abstract][Full Text] [Related]
13. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting.
Rodier SG; Bukur M; Moore S; Frangos SG; Tandon M; DiMaggio CJ; Ayoung-Chee P; Marshall GT
Eur J Trauma Emerg Surg; 2021 Feb; 47(1):145-151. PubMed ID: 31471669
[TBL] [Abstract][Full Text] [Related]
14. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
15. Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients.
Chanas T; Gibson G; Langenstroer E; Herrmann DJ; Carver TW; Alexander K; Chui SHJ; Rein L; Ha M; Maynard KM; Bamberg K; O'Keefe M; O'Brien M; Gonzalez MC; Hobbs B; Pajoumand M; Peppard WJ
Pharmacotherapy; 2024 Mar; 44(3):258-267. PubMed ID: 38148134
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Gates RS; Lollar DI; Collier BR; Smith J; Faulks ER; Gillen JR
J Trauma Acute Care Surg; 2022 Jan; 92(1):93-97. PubMed ID: 34561398
[TBL] [Abstract][Full Text] [Related]
17. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
18. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Martin AG; Lineen EB; Namias N; Schulman CI; Proctor KG
J Trauma Acute Care Surg; 2017 Dec; 83(6):1102-1107. PubMed ID: 29190255
[TBL] [Abstract][Full Text] [Related]
19. The ATLANTIC study: Anti-Xa level assessment in trauma intensive care.
Rakhra S; Martin EL; Fitzgerald M; Udy A
Injury; 2020 Jan; 51(1):10-14. PubMed ID: 31679829
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR
Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
